In Rwanda, cancer remains a leading health challenge, with breast, cervical, and prostate cancers being among the most prevalent. According to Dr. Theoneste Maniragaba, the Director of the Cancer ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

FLASH radiation therapy could one day cure complex tumors and cancers while limiting the toll of radiation on the body. France's Institut Curie hopes to install one of the special machines in its ...

Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti-PD-1 mAb, ...

Molecular profiling and genetic testing have revolutionised lung cancer treatment, says a doctor. They have enabled targeted therapies that are more effective and tolerable than traditional ...

Ariceum Therapeutics, a private biotech company based in Berlin, has announced that the US Food and Drug Administration (FDA) ...

The owners and staff of Woodstock Infusions (L-R): manager Tania Cawthron, owner and registered nurse Kim Rice, founder and owner Marc Baumslag and registered nurse Anna Schlosser. (Photos by Lauren ...

The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding “Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...